

Immune Design Corp.
Form 4
July 31, 2014

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Svennilson Peter

(Last) (First) (Middle)

C/O IMMUNE DESIGN
CORP., 1616 EASTLAKE AVE. E.,
SUITE 310

(Street)

SEATTLE, WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immune Design Corp. [IMDZ]

3. Date of Earliest Transaction
(Month/Day/Year)
07/29/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
				(A) or (D)	Price				
Common Stock	07/29/2014		C	733,943	A	Ⓐ	733,943	I (2)	See Footnote (2)
Common Stock	07/29/2014		C	744,580	A	Ⓐ	1,478,523	I (2)	See Footnote (2)
Common Stock	07/29/2014		C	856,269	A	Ⓐ	2,334,792	I (2)	See Footnote (2)
Common Stock	07/29/2014		C	428,134	A	Ⓐ	2,762,926	I (2)	See

Edgar Filing: Immune Design Corp. - Form 4

Stock								Footnote <u>(2)</u>
Common Stock	07/29/2014		P	399,016	A	\$ 12	3,161,942	I <u>(2)</u> See Footnote <u>(2)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Security (Instr. 3 and 4)	
					Code	V	(A)	(D)	Date Exercisable		Expiration Date
Series A Preferred Stock	<u>(1)</u>	07/29/2014		C			733,943	<u>(1)</u>	<u>(1)</u>	Common Stock	733
Series B Preferred Stock	<u>(1)</u>	07/29/2014		C			744,580	<u>(1)</u>	<u>(1)</u>	Common Stock	744
Series C Preferred Stock	<u>(1)</u>	07/29/2014		C			856,269	<u>(1)</u>	<u>(1)</u>	Common Stock	856
Series C Preferred Stock Warrant (right to buy)	\$ 8.175	07/29/2014		X			428,134	10/16/2013	<u>(3)</u>	Series C Preferred Stock	428
Series C Preferred Stock	<u>(1)</u>	07/29/2014		X			428,134	<u>(1)</u>	<u>(1)</u>	Common Stock	428
Series C Preferred Stock	<u>(1)</u>	07/29/2014		C			428,134	<u>(1)</u>	<u>(1)</u>	Common Stock	428

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Svennilson Peter C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE, WA 98102	X	X		

Signatures

/s/ Laura A. Berezin, Attorney-in-Fact	07/31/2014
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.
- (1) The securities are directly held by The Column Group, LP ("The Column Group") and indirectly held by The Column Group, GP, LP ("TCG GP"), the general partner of The Column Group. TCG GP has voting and dispositive power with respect to the shares owned by
- (2) The Column Group. Mr. Svennilson is a managing partner of TCG GP and may be deemed to have shared voting and dispositive power over the shares owned by The Column Group. Mr. Svennilson disclaims beneficial ownership of all shares held by The Column Group, except to the extent of his actual pecuniary interest therein.
- The warrants were set to expire on the earlier of: (a) October 15, 2015, (b) the latter of (i) 30 days after delivery to the warrant holder of the interim study report of a specified clinical trial by the Issuer or (ii) 30 days after notice to the warrant holder of the commencement of
- (3) patient recruitment for specified studies or trials by the Issuer, (c) a liquidation event of the Issuer or (d) the closing of the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.